Home PROTAC Molecule EGFR/PROTAC
Despite the approval of various Epidermal Growth Factor Receptor (EGFR) inhibitors for non-small-cell lung cancers (NSCLC) treatment, their clinical application is significantly hindered by acquired drug resistance and associated side effects. The emerging technology of Proteolysis Targeting Chimeras (PROTAC) presents a potential alternative strategy to address these challenges.
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :